Scientific news - Nature Communications: Albumedix and collaborators from Cambridge University publish new data on site-specific conjugation of proteins, such as albumin-based therapeutics.

19 Dec 2016

Goncalo Bernardes of Cambridge and Lisbon university and co-workers have developed a new cysteine-selective reagent for the specific conjugation of proteins. They found the Cys34 of albumin, often used for attachment of active pharmaceutical agents to albumin, to be particularly well suited in terms of its reactivity and stability. Additionally, Albumedix helped establish that conjugation to the Cys34 by the new chemistry did not alter the binding ability of albumin to the neonatal Fc receptor, which is required for its long circulatory half-life.

Read the full article

If you want to receive the latest news from Albumedix you can follow us on LinkedIn

You are also very welcome to contact us directly by emailing:







Send now